Pharma two b announces poster presentation on p2b001 at the annual meeting of the parkinson's disease study group

Kiryat ono, israel, dec. 05, 2024 (globe newswire) -- pharma two b , a private, late-stage pharmaceutical company developing innovative combination drugs for neurological disorders, today announced a poster presentation of integrated safety and efficacy data on p2b001 from its phase 2b and phase 3 studies in early-stage parkinson's disease (pd) patients. p2b001 is a fixed, low-dose extended-release (er) combination of pramipexole, 0.6 mg and rasagiline, 0.75 mg.  the data are being presented today by henry moore, m.d., associate professor of clinical neurology, university of miami, miller school of medicine, at the parkinson's study group (psg) 33 rd annual meeting in nashville, tn.
HEPA Ratings Summary
HEPA Quant Ranking